De Bruin et al: Role of PD-ECGF/TP in health and disease de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38, 349-358. Brostjan C, Bayer A, Zommer A, Gornikiewicz A, Roka S, Benko T, Yaghubian R, Jakesz R, Steger G, Gnant M, Friedl J, Stift A (2003) Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer 98, 2291-2301. Brown NS, Bicknell R (1998) Thymidine phosphorylase, 2deoxy-D-ribose and angiogenesis. Biochem J 334, 1-8. Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R (2000) Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 60, 6298-6302. Bunn HF, Higgins PJ (1981) Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213, 222-224. Cao D, Russell RL, Zhang D, Leffert JJ, Pizzorno G (2002) Uridine phosphorylase -/- murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62, 2313-2317. Carta MC, Mattana A, Camici M, Allegrini S, Tozzi MG, Sgarrella F (2001) Catabolism of exogenous deoxyinosine in cultured epithelial amniotic cells. Biochim Biophys Acta 1528, 74-80. Ciccolini J, Cuq P, Evrard A, Giacometti S, Pelegrin A, Aubert C, Cano JP, Milano G, Iliadis A (2001) Combination of thymidine phosphorylase gene transfer and deoxinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics 1, 133-139. Ciccolini J, Peillard L, Evrard A, Cuq P, Aubert C, Pelegrin A, Formento P, Milano G, Catalin J (2000) Enhanced antitumor activity of 5-fluorouracil in combination with 2'deoxyinosine in human colorectal cell lines and human colon tumor xenografts. Clin Cancer Res 6, 1529-1535. Creamer D, Jaggar R, Allen M, Bicknell R, Barker J (1997) Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 137, 851-855. Cuq P, Rouquet C, Evrard A, Ciccolini J, Vian L, Cano JP (2001) Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase. Br J Cancer 84, 1677-1680. De Bruin M, Smid K, Laan AC, Noordhuis P, Fukushima M, Hoekman K, Pinedo HM, Peters GJ (2003a) Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Commun 301, 675-679. De Bruin M, Van Capel T, Smid K, Van der Born K, Fukushima M, Hoekman K, Pinedo HM, Peters GJ (2004) Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate. Nucleosides Nucleotides Nucleic Acids 23, 1485-1490. De Bruin M, Van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM, Peters GJ (2003b) Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 88, 957-964. Dexter DL, Wolberg WH, Ansfield FJ, Helson L, Heidelberger C (1972) The clinical pharmacology of 5-trifluoromethyl-2'deoxyuridine. Cancer Res 32, 247-253.
Eckstein JW, Foster PG, Finer-Moore J, Wataya Y, Santi DV (1994) Mechanism-based inhibition of thymidylate synthase by 5- trifluoromethyl -2'-deoxyuridine 5'-monophosphate. Biochemistry 33, 15086-15094. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H (1993) Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32, 333-338. el Kouni MH, el Kouni MM, Naguib FN (1993) Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines (published erratum in Cancer Res 1993 ;53:4738). Cancer Res 53, 3687-3693. Emura T, Nakagawa F, Fujioka A, Ohshimo H, Kitazato K (2004a) Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS102 in a mouse model. Oncol Rep 11, 381-387. Emura T, Nakagawa F, Fujioka A, Ohshimo H, Yokogawa T, Okabe H, Kitazato K (2004b) An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 13, 249-255. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83, 127-134. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL (1997) Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. J Pathol 182, 414-420. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP (1999a) Increased cytotoxicity and bystander effect of 5-fluorouracil and 5'deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 80, 1726-1733. Evrard A, Cuq P, Robert B, Vian L, Pelegrin A, Cano JP (1999b) Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study. Int J Cancer 80, 465-470. Finnis C, Dodsworth N, Pollitt CE, Carr G, Sleep D (1993) Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. Eur J Biochem 212, 201-210. Focher F, Spadari S (2001) Thymidine phosphorylase: a two-face Janus in anticancer chemotherapy. Curr Cancer Drug Targets 1, 141-153. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31. Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL (1997) Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 8, 271-275. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL (1995) Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 176, 183190. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC, Harris AL (1996) The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73, 275-280. Fujii S, Kitano S, Ikenaka K, Shirasaka T (1979) Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1- 2-tetrahydrofuryl -5-
116